Kai Niu1, Yanling Liu2, Zijun Zhou3, Xuefeng Wu4, Huaiwu Wang5, Jingzhe Yan6. 1. Department of Thoracic Oncology, Jilin Province Cancer Hospital, Changchun, Jilin 130012, China. 2. Department of Internal Medicine, Jilin Province Cancer Hospital, Changchun, Jilin 130012, China. 3. Department of Breast Surgery, Jilin Province Cancer Hospital, Changchun, Jilin 130012, China. 4. Department of Clinical Laboratory, Jilin Province Cancer Hospital, Changchun, Jilin 130012, China. 5. Department of Anesthesiology, Jilin Province Cancer Hospital, Changchun, Jilin 130012, China. 6. Department of Abdominal Oncosurgery, Jilin Province Cancer Hospital, Changchun, Jilin 130012, China.
Abstract
BACKGROUND: Paeoniflorin has been reported to exert antitumor effects on human cancers. However, the role of paeoniflorin in gastric cancer and the underlying molecular mechanism are unelucidated. Therefore, we determined whether paeoniflorin could exhibit anticancer activity in gastric cancer cells. METHODS: MTT was used to measure the viability of cells after paeoniflorin treatment. FACS was performed to examine cell apoptosis. Wound healing and transwell invasion assays were conducted to examine cell migratory and invasive activities. Western blotting was used to explore the mechanism by which paeoniflorin exerted tumor suppressive effects. RESULTS: We found that paeoniflorin suppressed cell growth, enhanced apoptosis, and reduced cell invasion. Notably, we showed that paeoniflorin inhibited the expression of TAZ in gastric cancer cells. The overexpression of TAZ abrogated the antitumor activity of paeoniflorin in gastric cancer cells. In contrast, the downregulation of TAZ promoted the tumor suppressive effects of paeoniflorin treatment. CONCLUSION: Hence, targeting TAZ with paeoniflorin could be a novel approach for the treatment of human gastric cancer.
BACKGROUND: Paeoniflorin has been reported to exert antitumor effects on human cancers. However, the role of paeoniflorin in gastric cancer and the underlying molecular mechanism are unelucidated. Therefore, we determined whether paeoniflorin could exhibit anticancer activity in gastric cancer cells. METHODS: MTT was used to measure the viability of cells after paeoniflorin treatment. FACS was performed to examine cell apoptosis. Wound healing and transwell invasion assays were conducted to examine cell migratory and invasive activities. Western blotting was used to explore the mechanism by which paeoniflorin exerted tumor suppressive effects. RESULTS: We found that paeoniflorin suppressed cell growth, enhanced apoptosis, and reduced cell invasion. Notably, we showed that paeoniflorin inhibited the expression of TAZ in gastric cancer cells. The overexpression of TAZ abrogated the antitumor activity of paeoniflorin in gastric cancer cells. In contrast, the downregulation of TAZ promoted the tumor suppressive effects of paeoniflorin treatment. CONCLUSION: Hence, targeting TAZ with paeoniflorin could be a novel approach for the treatment of human gastric cancer.